J&J's two-drug combo blocked tumors in advanced multiple myeloma

ASH 2025 had both rain and sun, positive and negative data in Orlando, Fla.ASH 2025 was in Orlando, Fla. Adam Feuerstein / STAT

This is the web version of ASH in 30 Seconds, STAT’s report from the American Society of Hematology meeting.

And on the last day of ASH, the sun shone once again. Thanks for joining us on this hematology-oncology journey. We hope you’ve enjoyed our coverage. Until next year, in New Orleans!

J&J’s ‘Tec-Dara’ combo shines in multiple myeloma study

A two-drug regimen from Johnson & Johnson showed an unprecedented tumor-progression benefit compared to the standard of care for patients with relapsed or refractory multiple myeloma, according to results from a Phase 3 study presented today.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized by national Edward R. Murrow awards, the June L. Biedler prize for cancer journalism, and more. You can reach Angus on Signal at angus.08.

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT’s industry-leading events.